LTC1436271I2 - Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai - Google Patents

Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai

Info

Publication number
LTC1436271I2
LTC1436271I2 LTPA2014013C LTPA2014013C LTC1436271I2 LT C1436271 I2 LTC1436271 I2 LT C1436271I2 LT PA2014013 C LTPA2014013 C LT PA2014013C LT PA2014013 C LTPA2014013 C LT PA2014013C LT C1436271 I2 LTC1436271 I2 LT C1436271I2
Authority
LT
Lithuania
Prior art keywords
serotonin reuptake
reuptake inhibitors
phenylpiperazine derivatives
phenylpiperazine
derivatives
Prior art date
Application number
LTPA2014013C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1436271(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of LTPA2014013I1 publication Critical patent/LTPA2014013I1/lt
Publication of LTC1436271I2 publication Critical patent/LTC1436271I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LTPA2014013C 2001-10-04 2014-03-13 Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai LTC1436271I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
LTPA2014013I1 LTPA2014013I1 (lt) 2014-04-25
LTC1436271I2 true LTC1436271I2 (lt) 2016-09-12

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2014013C LTC1436271I2 (lt) 2001-10-04 2014-03-13 Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai

Country Status (38)

Country Link
US (10) US7144884B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1749818B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP3896116B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100842702B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1319958C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR036659A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE441631T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2002333220C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C036I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0212733B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2462110C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5580746A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1107924T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE60233608D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1749818T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA007537B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG25095A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2328725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0033I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040220A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HU230189B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL160655A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2578B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1436271I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92397I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00039B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04002959A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY140950A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300652I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO326443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ531556A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL210551B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1749818E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS52865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1436271T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (2) UA81749C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003029232A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200401583B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
SI1635828T1 (sl) * 2003-04-04 2008-08-31 Lundbeck & Co As H Derivati 4-(2-feniloksifenil)-piperidina ali-1,2,3,6-tetrahidropiridina kot inhibitorji ponovnega privzema serotonina
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
CN1780622A (zh) * 2003-04-04 2006-05-31 H.隆德贝克有限公司 作为5－羟色胺再摄取抑制剂的4－(2－苯基硫烷基－苯基)－哌啶衍生物
DK1626720T3 (da) * 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
CL2004000726A1 (es) * 2003-04-04 2005-05-20 Lundbeck & Co As H Compuestos derivados de 4-[2-(feniloxi sustituido)fenil]piperidina o -1,2,3,6-tetrahidropiridina; composcion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansi
SI1701940T1 (sl) 2003-12-23 2008-10-31 Lundbeck & Co As H 2-(1h-indolilsulfanil)-benzil aminski derivati kot ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) * 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EP2044020B1 (en) 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
HRP20120173T4 (hr) * 2006-06-16 2021-04-16 H. Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao spoj s kombiniranom aktivnošću na ponovnu pohranu serotonina, 5-ht3 i 5-ht1a za liječenje kognitivnih poremećaja
SI2044020T1 (sl) * 2006-06-16 2011-06-30 Lundbeck & Co As H Kristaliniäśne oblike 4-(2-(4-metilfenilsulfanil)-fenil)piperidina s kombiniranim zaviranjem ponovnega privzema serotonina in norepinefrina za zdravljenje nevropatske boleäśine
CN101472891B (zh) * 2006-06-16 2013-08-21 H.隆德贝克有限公司 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
TWI441810B (zh) 2008-11-14 2014-06-21 Theravance Inc ４－［２－（２，４，６－三氟苯氧基甲基）苯基］－哌啶之結晶鹽酸鹽及其醫藥組合物、製法及用途
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
DK2421534T3 (da) * 2009-04-24 2014-10-13 Lundbeck & Co As H Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
EP2470166B1 (en) 2009-08-24 2013-08-14 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
WO2011053706A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
JP5705239B2 (ja) * 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CA2797812C (en) * 2010-04-30 2018-02-20 Takeda Pharmaceutical Company Limited Enteric tablet
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HUE044043T2 (hu) 2011-06-20 2019-09-30 H Lundbeck As Deuterizált 1-piperazino-3-fenil-indánok skizofrénia kezelésére
EP2780467B1 (en) 2011-11-14 2018-10-17 Alfasigma S.p.A. Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
CA2860103C (en) * 2012-01-03 2020-07-07 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
MX362886B (es) 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
AU2014220735B2 (en) 2013-02-22 2017-06-22 H. Lundbeck A/S Vortioxetine manufacturing process
WO2014161976A1 (en) * 2013-04-04 2014-10-09 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
KR20160093025A (ko) 2013-12-20 2016-08-05 하. 룬트벡 아크티에 셀스카브 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016135636A1 (en) 2015-02-25 2016-09-01 Lupin Limited Process for the preparation of vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
JP7000321B2 (ja) * 2015-07-17 2022-02-10 アンスティテュ・パストゥール 衛星細胞の自己再生および／または分化の促進剤としての使用のための５－ヒドロキシトリプタミン１ｂ受容体刺激剤
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
WO2018002115A1 (en) * 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
EP3484462B1 (en) * 2016-07-15 2022-12-14 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
EP3489225A4 (en) * 2016-07-22 2019-12-18 Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. ANALOG OF VORTIOXETINE, ITS USE AND ITS PREPARATION
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
RS62823B1 (sr) * 2017-04-25 2022-02-28 H Lundbeck As Postupak za proizvodnju alfa-oblika vortioksetin hbr-a
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
ES2976985T3 (es) 2018-06-20 2024-08-14 Vio Ag Pharmaceuticals S A Enfoque de activación C-H organo-pseudocatalítica de un recipiente para la preparación de vortioxetina y producto intermedio de vortioxetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151753B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151752B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151751B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
CS151755B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
US6048876A (en) * 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2230209T3 (es) * 1997-10-31 2005-05-01 Daiichi Suntory Pharma Co., Ltd. Procedimiento para preparar n-((4-fenil)metilfenil)piperazinas.
CN1721401A (zh) 1999-04-02 2006-01-18 伊科斯公司 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
WO2001019678A1 (en) * 1999-09-14 2001-03-22 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
EP1246819A1 (en) * 1999-12-30 2002-10-09 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
KR100790916B1 (ko) * 1999-12-30 2008-01-03 하. 룬트벡 아크티에 셀스카브 치환 페닐-피페라진 유도체, 그들의 제조 및 사용
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
ES2246390T3 (es) * 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
DK1626720T3 (da) * 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
HRP20120173T4 (hr) * 2006-06-16 2021-04-16 H. Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao spoj s kombiniranom aktivnošću na ponovnu pohranu serotonina, 5-ht3 i 5-ht1a za liječenje kognitivnih poremećaja

Also Published As

Publication number Publication date
NO326443B1 (no) 2008-12-08
US20110009423A1 (en) 2011-01-13
UA81749C2 (uk) 2008-02-11
US7683053B2 (en) 2010-03-23
KR20070103515A (ko) 2007-10-23
PL368442A1 (pl) 2005-03-21
ZA200401583B (en) 2005-05-25
BR122012023120B1 (pt) 2017-03-21
EP1749818A3 (en) 2008-04-02
HUP0402313A2 (hu) 2005-02-28
MY140950A (en) 2010-02-12
US9708280B2 (en) 2017-07-18
NL300652I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-18
DK1436271T3 (da) 2008-06-09
HRP20040220A2 (en) 2005-02-28
JP2007031447A (ja) 2007-02-08
KR100842702B1 (ko) 2008-07-01
SI1436271T1 (sl) 2008-06-30
AU2006215994B2 (en) 2008-11-13
JP3955613B2 (ja) 2007-08-08
BR0212733A (pt) 2004-11-16
US8476279B2 (en) 2013-07-02
EP1436271A1 (en) 2004-07-14
HK1072600A1 (zh) 2005-09-02
HUP0402313A3 (en) 2010-03-29
ATE441631T1 (de) 2009-09-15
US20070060574A1 (en) 2007-03-15
AU2002333220B2 (en) 2008-02-07
IS8806A (is) 2009-03-10
PL209253B1 (pl) 2011-08-31
US20160137620A1 (en) 2016-05-19
CN1319958C (zh) 2007-06-06
JP3955614B2 (ja) 2007-08-08
HU228956B1 (en) 2013-07-29
HUS1400012I1 (hu) 2020-12-28
JP3896116B2 (ja) 2007-03-22
PL210551B1 (pl) 2012-02-29
EA200601269A1 (ru) 2007-02-27
EP1436271B3 (en) 2022-04-20
AU2002333220A2 (en) 2003-04-14
AU2006215994A2 (en) 2006-10-05
BR122012023120B8 (pt) 2022-01-18
US20120302553A1 (en) 2012-11-29
BRPI0212733B8 (pt) 2021-05-25
BR0212733B1 (pt) 2014-05-13
DK1436271T6 (da) 2022-06-27
CY1107924T1 (el) 2013-09-04
EA007537B3 (ru) 2015-02-27
IS2578B (is) 2010-02-15
EP1749818A2 (en) 2007-02-07
IS7164A (is) 2004-02-26
CY2014022I2 (el) 2015-12-09
BR122012009534B1 (pt) 2018-02-27
LTPA2014013I1 (lt) 2014-04-25
HU230189B1 (hu) 2015-09-28
US20210276966A1 (en) 2021-09-09
US20060084662A1 (en) 2006-04-20
MEP6508A (xx) 2010-02-10
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
PT1749818E (pt) 2009-10-06
US7148238B2 (en) 2006-12-12
NO332355B1 (no) 2012-09-03
JP2007051149A (ja) 2007-03-01
BR122012009534B8 (pt) 2019-01-29
ES2328725T3 (es) 2009-11-17
US7138407B2 (en) 2006-11-21
KR20060118020A (ko) 2006-11-17
FR14C0033I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-06-13
CA2462110A1 (en) 2003-04-10
AU2006215994A1 (en) 2006-10-05
EA011096B1 (ru) 2008-12-30
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
RS52865B (sr) 2013-12-31
US9090575B2 (en) 2015-07-28
CN1561336A (zh) 2005-01-05
RS27704A (sr) 2006-10-27
RS20120158A2 (sr) 2012-10-31
EG25095A (en) 2011-08-17
CY1110064T1 (el) 2015-01-14
AU2002333220C1 (en) 2023-10-05
ME00039B (me) 2010-06-10
WO2003029232A1 (en) 2003-04-10
KR20040047886A (ko) 2004-06-05
AR066460A2 (es) 2009-08-19
ES2298425T3 (es) 2008-05-16
ATE386730T1 (de) 2008-03-15
KR100770194B1 (ko) 2007-10-25
US20050014740A1 (en) 2005-01-20
DK1749818T3 (da) 2009-10-12
US20060089368A1 (en) 2006-04-27
NO2014011I1 (no) 2014-05-13
AU2006215994A9 (en) 2006-10-05
EP1436271B1 (en) 2008-02-20
NO2014011I2 (no) 2015-08-31
MXPA04002959A (es) 2004-07-05
US20140163043A1 (en) 2014-06-12
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
CO5580746A2 (es) 2005-11-30
IL160655A0 (en) 2004-07-25
CA2462110C (en) 2010-05-11
CA2462110E (en) 2003-04-10
AR036659A1 (es) 2004-09-22
ES2298425T7 (es) 2022-06-27
NO20083446L (no) 2004-04-21
US10844029B2 (en) 2020-11-24
US7144884B2 (en) 2006-12-05
DE60233608D1 (de) 2009-10-15
CY2014022I1 (el) 2015-12-09
JP2005505585A (ja) 2005-02-24
NO20041628L (no) 2004-04-21
KR100783346B1 (ko) 2007-12-07
EP1749818B1 (en) 2009-09-02
DE60225162T2 (de) 2009-02-12
FR14C0033I2 (fr) 2014-11-14
US20180127389A1 (en) 2018-05-10
BE2014C036I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-11-22
NL300652I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-18
RS20120158A3 (en) 2013-10-31
DE60225162D1 (de) 2008-04-03
PT1436271E (pt) 2008-04-10
IS2732B (is) 2011-04-15
EA007537B1 (ru) 2006-10-27
UA93857C2 (uk) 2011-03-25
EA200400498A1 (ru) 2004-08-26

Similar Documents

Publication Publication Date Title
LTC1436271I2 (lt) Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
NO20034307D0 (no) Cyklopropylindol-derivater som selektive serotonin- gjenopptaksinhibitorer
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20030842D0 (no) Fenoksybenzylamin-derivater som selektive serotonin- gjenopptaksinhibitorer
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DK1212320T3 (da) Phenylpiperazinderivater som inhibitorer for genoptag af serotonin
AP2005003467A0 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
EE200300498A (et) Fenüül-heterotsüklüüleetri derivaadid kui serotoniini tagasihaarde inhibiitorid
NO20035248D0 (no) Nye fenylalkyloksy-fenyl derivater
DK1682523T3 (da) Morpholin-derivater som noradrenalin-genoptagelsesinhibitorer
IS8827A (is) 2-(1H-indólýlsúlfanýl)-bensýl amín afleiður sem valvís serótónín endurupptöku hindri (SSR).
NO20040913L (no) Nye 2,4-diaminotiazolderivater
HK1060563A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
DK1377550T3 (da) Phenyl-heterocyclyletherderivater som serotonin-re-uptakeinhibitorer
DK1287001T3 (da) Thiophenderivater, der er egnede som anticancermidler